Javier Molina Cerrillo, Attending Physician in Medical Oncology at Hospital Ramón y Cajal, shared a post on LinkedIn:
“Is triple therapy enough in renal cell carcinoma (RCC)?
I’m pleased to share our new article, published in ESMO Open, addressing an important question in the evolving treatment landscape of RCC.
Despite major advances in combination strategies, triple therapy is not the end of the story. More intensive treatment does not necessarily translate into durable disease control for every patient, and important challenges remain in balancing efficacy, toxicity, and long-term outcomes.We discussed it in a recent editorial here.
–
Title: Triplet Therapy in Metastatic Clear Cell Renal Cell Carcinoma: Time to Abandon Empiric, Biomarker-unselected Intensification?
Authors: Javier Molina-Cerrilloa, Victoria Gómez Dos Santosc, Teresa Alonso-Gordoaa
–
Title: A randomised, open-label, phase II study of tobemstomig combinations in patients with previously untreated advanced clear-cell renal cell carcinoma
Authors: Brian Rini, T. Powles, P. Tomczak, S.J. Shin, J. Guo, J. Molina-Cerrillo, X. Ren, J.L. Lee, P.J. Wysocki, J. Puente, A. Basu, N. Mar, S. Bernhard, O. Khan, J. Ha, L. Colley, H. Prizant, L. Albiges
–
The next step in RCC treatment should not simply be adding more drugs, but identifying the right strategies for the right patients.
I invite you to read our new publication and join the discussion.”
You can also read:
The Growing Gap in Renal Cell Carcinoma Treatment in Brazil
